Login to Your Account

In The Clinic NEWS

After the success by Shire plc with its injectable kallikrein inhibitor, lanadelumab, for HAE, investor hopes swelled for Biocryst Pharmaceuticals Inc.'s oral BCX-7353.

Reporting top-line data from the first phase IIa segment of its ACHIEVE study of SB-9200 in patients with chronic HBV, Spring Bank Pharmaceuticals Inc. suggested its lead candidate more than met its mark.

Encouraged but still cautious, Dan Teleman, CEO of Atox Bio Ltd., was careful not to raise expectations about the eventual outcome of the ongoing phase III ACCUTE.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: